Literature DB >> 22512753

Immune responses to cholera in children.

Daniel T Leung1, Fahima Chowdhury, Stephen B Calderwood, Firdausi Qadri, Edward T Ryan.   

Abstract

Cholera is a severe acute dehydrating diarrheal disease caused by Vibrio cholerae O1 or O139 infection, and is associated with significant mortality and morbidity globally. Although young children bear a high burden of the disease, currently available oral vaccines give a lower efficacy and shorter duration of protection in this group than in adults. According to the studies of natural infection, young children achieve comparable systemic anti-V. cholerae antigen-specific antibody, gut-homing antibody-secreting cell and memory B-cell responses as adults. Studies on innate and cell-mediated immune responses are lacking in children, and may offer important insights into differences in vaccine efficacy. The impact of host factors such as malnutrition, genetics and coinfection with other pathogens also remains to be fully defined.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22512753      PMCID: PMC3378723          DOI: 10.1586/eri.12.23

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  105 in total

Review 1.  The true burden and risk of cholera: implications for prevention and control.

Authors:  Jane N Zuckerman; Lars Rombo; Alain Fisch
Journal:  Lancet Infect Dis       Date:  2007-08       Impact factor: 25.071

Review 2.  Maternal and child undernutrition: global and regional exposures and health consequences.

Authors:  Robert E Black; Lindsay H Allen; Zulfiqar A Bhutta; Laura E Caulfield; Mercedes de Onis; Majid Ezzati; Colin Mathers; Juan Rivera
Journal:  Lancet       Date:  2008-01-19       Impact factor: 79.321

3.  Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants.

Authors:  Firdausi Qadri; Mohiul I Chowdhury; Shah M Faruque; Mohammed A Salam; Tanvir Ahmed; Yasmin A Begum; Amit Saha; Abdullah Al Tarique; Lorenz V Seidlein; Eunsik Park; Kevin P Killeen; John J Mekalanos; John D Clemens; David A Sack
Journal:  Vaccine       Date:  2006-09-05       Impact factor: 3.641

4.  Single-dose azithromycin for the treatment of cholera in adults.

Authors:  Debasish Saha; Mohammad M Karim; Wasif A Khan; Sabeena Ahmed; Mohammed A Salam; Michael L Bennish
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

5.  Broad up-regulation of innate defense factors during acute cholera.

Authors:  Carl-Fredrik Flach; Firdausi Qadri; Taufiqur R Bhuiyan; Nur H Alam; Eva Jennische; Ivar Lönnroth; Jan Holmgren
Journal:  Infect Immun       Date:  2007-02-16       Impact factor: 3.441

6.  Intestinal parasitism and Vibrio cholerae infection among diarrhoeal patients in Kolkata, India.

Authors:  D R Saha; K Rajendran; T Ramamurthy; R K Nandy; S K Bhattacharya
Journal:  Epidemiol Infect       Date:  2007-06-26       Impact factor: 2.451

7.  Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine.

Authors:  Elizabeth A Clutterbuck; Sarah Oh; Mainga Hamaluba; Sharon Westcar; Peter C L Beverley; Andrew J Pollard
Journal:  Clin Vaccine Immunol       Date:  2007-11-21

8.  Role of zinc administration in prevention of childhood diarrhea and respiratory illnesses: a meta-analysis.

Authors:  Rakesh Aggarwal; John Sentz; Mark A Miller
Journal:  Pediatrics       Date:  2007-06       Impact factor: 7.124

9.  Zinc supplementation in children with cholera in Bangladesh: randomised controlled trial.

Authors:  S K Roy; M Jahangir Hossain; Wajiha Khatun; Barnali Chakraborty; S Chowdhury; Afroza Begum; Syeda Mah-e-Muneer; Sohana Shafique; Mansura Khanam; R Chowdhury
Journal:  BMJ       Date:  2008-01-08

10.  The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa.

Authors:  Jacqueline L Deen; Lorenz von Seidlein; Dipika Sur; Magdarina Agtini; Marcelino E S Lucas; Anna Lena Lopez; Deok Ryun Kim; Mohammad Ali; John D Clemens
Journal:  PLoS Negl Trop Dis       Date:  2008-02-20
View more
  21 in total

1.  Immunochemical characterization of synthetic hexa-, octa- and decasaccharide conjugate vaccines for Vibrio cholerae O:1 serotype Ogawa with emphasis on antigenic density and chain length.

Authors:  Peter Ftacek; Victor Nelson; Shousun C Szu
Journal:  Glycoconj J       Date:  2013-08-17       Impact factor: 2.916

2.  Insights from natural infection-derived immunity to cholera instruct vaccine efforts.

Authors:  Marcela F Pasetti; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

3.  Enumeration of Gut-Homing β7-Positive, Pathogen-Specific Antibody-Secreting Cells in Whole Blood from Enterotoxigenic Escherichia coli- and Vibrio cholerae-Infected Patients, Determined Using an Enzyme-Linked Immunosorbent Spot Assay Technique.

Authors:  Taufiqur Rahman Bhuiyan; Mohammad Rubel Hoq; Naoshin Sharmin Nishat; Deena Al Mahbuba; Rasheduzzaman Rashu; Kamrul Islam; Lazina Hossain; Ayan Dey; Jason B Harris; Edward T Ryan; Stephen B Calderwood; Ann-Mari Svennerholm; Firdausi Qadri
Journal:  Clin Vaccine Immunol       Date:  2015-10-28

4.  Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.

Authors:  Russell A Johnson; Taher Uddin; Amena Aktar; M Mohasin; Mohammad Murshid Alam; Fahima Chowdhury; Jason B Harris; Regina C LaRocque; Meagan Kelly Bufano; Yanan Yu; Ying Wu-Freeman; Daniel T Leung; David Sarracino; Bryan Krastins; Richelle C Charles; Peng Xu; Pavol Kovác; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

Review 5.  Diagnosis, Management, and Future Control of Cholera.

Authors:  Fahima Chowdhury; Allen G Ross; Md Taufiqul Islam; Nigel A J McMillan; Firdausi Qadri
Journal:  Clin Microbiol Rev       Date:  2022-06-21       Impact factor: 50.129

6.  Antibody avidity in humoral immune responses in Bangladeshi children and adults following administration of an oral killed cholera vaccine.

Authors:  Mohammad Murshid Alam; Daniel T Leung; Marjahan Akhtar; Mohammad Nazim; Sarmin Akter; Taher Uddin; Farhana Khanam; Deena Al Mahbuba; Shaikh Meshbahuddin Ahmad; Taufiqur Rahman Bhuiyan; Stephen B Calderwood; Edward T Ryan; Firdausi Qadri
Journal:  Clin Vaccine Immunol       Date:  2013-08-07

7.  Assessing antigen specific HLA-DR+ antibody secreting cell (DR+ASC) responses in whole blood in enteric infections using an ELISPOT technique.

Authors:  Taufiqur Rahman Bhuiyan; Mohammad Rubel Hoq; Naoshin Sharmin Nishat; Deena Al Mahbuba; Rasheduzzaman Rashu; Kamrul Islam; Lazina Hossain; Jason B Harris; Edward T Ryan; Stephen B Calderwood; Ann-Mari Svennerholm; Firdausi Qadri
Journal:  Microbes Infect       Date:  2017-11-08       Impact factor: 2.700

8.  A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.

Authors:  Sachin N Desai; Zenebe Akalu; Samuel Teshome; Mekonnen Teferi; Lawrence Yamuah; Deok Ryun Kim; Jae Seung Yang; Jemal Hussein; Ju Yeong Park; Mi Seon Jang; Chalachew Mesganaw; Hawult Taye; Demissew Beyene; Ahmed Bedru; Ajit Pal Singh; Thomas F Wierzba; Abraham Aseffa
Journal:  Am J Trop Med Hyg       Date:  2015-06-15       Impact factor: 2.345

Review 9.  Cholera toxin B: one subunit with many pharmaceutical applications.

Authors:  Keegan J Baldauf; Joshua M Royal; Krystal Teasley Hamorsky; Nobuyuki Matoba
Journal:  Toxins (Basel)       Date:  2015-03-20       Impact factor: 4.546

10.  Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide.

Authors:  Mohammad Murshid Alam; Megan Kelly Bufano; Peng Xu; Anuj Kalsy; Y Yu; Y Wu Freeman; Tania Sultana; Md Rasheduzzaman Rashu; Ishaan Desai; Grace Eckhoff; Daniel T Leung; Richelle C Charles; Regina C LaRocque; Jason B Harris; John D Clements; Stephen B Calderwood; Firdausi Qadri; W F Vann; Pavol Kováč; Edward T Ryan
Journal:  PLoS Negl Trop Dis       Date:  2014-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.